GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care

医学 重症监护医学 慢性阻塞性肺病 药物治疗 个性化医疗 梅德林 肺病 疾病管理 精密医学 金标准(测试) 护理标准 医疗保健 内科学 生活质量(医疗保健)
作者
Mario Cazzola,Jyoti Bajpai,Luigino Calzetta,Maria Gabriella Matera,Paola Rogliani
出处
期刊:Drugs [Adis, Springer Healthcare]
卷期号:86 (5): 581-597 被引量:27
标识
DOI:10.1007/s40265-026-02303-3
摘要

The 2026 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) introduces substantial conceptual and practical updates to the management of chronic obstructive pulmonary disease. While maintaining the established spirometric definition, the report emphasizes early diagnosis, multi-dimensional assessment, and personalized treatment strategies that move beyond a spirometry-centric approach. Key innovations include formally recognizing disease activity as a therapeutic target, refining the ABE classification with a lower threshold for patients prone to exacerbations (Group E), and integrating blood eosinophil counts to guide inhaled corticosteroid therapy. Nonpharmacologic interventions, such as pulmonary rehabilitation, vaccination, smoking cessation, structured self-management, and post-exacerbation care, are elevated to core disease-modifying strategies. Pharmacological escalation is structured around dual bronchodilation as the preferred initial step, with further intensification to biomarker-guided triple therapy, including inhaled corticosteroids or other anti-inflammatory agents, reserved for selected patients who remain symptomatic or experience exacerbations despite optimized dual therapy. GOLD 2026 also introduces biologics, dupilumab and mepolizumab, as an add-on therapy for exacerbation-prone eosinophilic chronic obstructive pulmonary disease. However, it also highlights ongoing limitations in efficacy, cost effectiveness, and generalizability. Artificial intelligence and emerging digital technologies are recognized as promising adjuncts in the management of chronic obstructive pulmonary disease, though their clinical implementation remains preliminary. Overall, GOLD 2026 advances precision medicine in chronic obstructive pulmonary disease by combining structured individualized assessments with early targeted interventions. However, significant uncertainties remain, including biological variability of biomarkers, limited evidence for emerging therapies, and barriers to equitable access to nonpharmacologic and advanced interventions. Careful context-sensitive application and continued validation are essential.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin的应助被planb采纳,获得10
1秒前
要文献啊完成签到 ,获得积分10
1秒前
嘿哈哈哈哈完成签到,获得积分20
1秒前
11111完成签到,获得积分10
1秒前
1秒前
Munchr1发布了新的文献求助10
1秒前
orixero的应助被芋泥啵啵采纳,获得10
1秒前
2秒前
man完成签到,获得积分20
3秒前
amia完成签到,获得积分10
3秒前
4秒前
4秒前
xx发布了新的文献求助10
4秒前
cherish发布了新的文献求助10
4秒前
皮卡丘发布了新的文献求助10
5秒前
5秒前
zxk发布了新的文献求助10
5秒前
5秒前
6秒前
容与完成签到 ,获得积分10
6秒前
余香的应助被amia采纳,获得10
7秒前
xiongjie发布了新的文献求助10
8秒前
man发布了新的文献求助30
8秒前
yang发布了新的文献求助10
8秒前
酷波er的应助被Lu采纳,获得10
8秒前
Munchr1完成签到,获得积分10
8秒前
10秒前
369ninja发布了新的文献求助10
10秒前
8895发布了新的文献求助10
12秒前
13秒前
14秒前
JamesPei的应助被dianhuaxue采纳,获得10
14秒前
14秒前
小馋猫完成签到,获得积分10
15秒前
yang发布了新的文献求助10
16秒前
liu1223456完成签到,获得积分10
16秒前
ihuu完成签到,获得积分10
16秒前
李健的应助被耳东采纳,获得10
17秒前
18秒前
可爱的函函的应助被勿忘采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817